GENE ONLINE|News &
Opinion
Blog

Targeted Radioligand Therapy
M&A Eli LillyRadiopharmaceutical
Eli Lilly Expands Oncology Portfolio with $1.4 Billion Acquisition of POINT Biopharma
2023-10-04
Interviews Rakuten Medical
Defeating Head and Neck Cancer, From Combination Therapy to Photoimmunotherapy
2022-09-15
Day 3 ASCO 2021 Roundup: Lynparza, Keytruda and Novartis’ Radioligand Therapy Take Honors in Plenary Session
2021-06-09
Trials & Approvals Targeted Radioligand Therapy
Novartis’ Acquired Asset from Endocyte Shines in Phase 3 Prostate Cancer Trial
2021-03-24
LATEST
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
READ MORE
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top